ClinicalTrials.gg
RecruitingNCT05587127Updated Sep 25, 2025

Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia

An interventional study of Cognitive Behavioral Therapy in Avoidant/Restrictive Food Intake Disorder, Dyspepsia and Feeding and Eating Disorders, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Nov 2022; still recruiting 3 years 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Randomized controlled trial of an exposure-based behavioral treatment (CBT) in adults with functional dyspepsia who meet criteria for avoidant/restrictive food intake disorder (ARFID) with weight loss.

Read the detailed description

The purpose of this study is to conduct a randomized controlled trial (RCT) of a cognitive-behavioral treatment (CBT) compared to usual care as the control with adults with functional dyspepsia who also meet criteria for avoidant/restrictive food intake disorder (ARFID). Participants randomized into the CBT group will receive eight 1-hour sessions delivered weekly via the MGH-approved secure video platform Enterprise Zoom while the usual care group will be allowed to continue with treatment they are already receiving at the time of randomization. Participants in the usual care group will be offered CBT after study participation. We will determine the feasibility and acceptability of the CBT and explore changes in clinical outcomes and preliminary mechanisms.

02

Conditions studied

  • Avoidant/Restrictive Food Intake Disorder
  • Dyspepsia
  • Feeding and Eating Disorders
  • Cognitive Behavioral Therapy
  • Appetite Regulation
  • Functional Dyspepsia
  • Post-prandial Distress Syndrome
  • Behavioral Medicine
03

In context

Avoidant Restrictive Food Intake Disorder

40 studies on the registry are indexed under Avoidant Restrictive Food Intake Disorder; 12 are open to participants now.

This study's planned enrollment of 50 is above the median of 38 across 28 interventional studies indexed under Avoidant Restrictive Food Intake Disorder.

Browse Avoidant Restrictive Food Intake Disorder studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,586 studies on the registry; 447 are open to participants now.

Of its 222 completed or terminated interventional studies of FDA-regulated products, 168 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age at least 18 years at screening visit
  • Rome IV Functional Dyspepsia post-prandial distress type (with or without epigastric pain syndrome)
  • Negative upper endoscopy or upper radiographic GI series to rule out structural/organic cause for FD
  • Avoidant/Restrictive Food Intake Disorder (ARFID) diagnosis (by the Structured Clinical Interview for ; SCID-5 at Screening visit)
  • ≥5% weight loss from weight after functional dyspepsia symptom onset (at Screening visit)
  • Stable for outpatient care (based on the American Psychiatric Association Practice Guideline for the Treatment of Patients with Eating Disorders)
  • No previous history of CBT for functional dyspepsia or ARFID
  • Computer/internet webcam access
  • Fluency in English
  • Stable dose for 30 days if on any medication

Exclusion criteria

Exclusion Criteria

  • Inability to provide
  • Presence of other conditions that could explain the patient's symptoms by chart:

Pyloric or intestinal obstruction (by EGD, UGI, or Abdominal CT) Active H.pylori infection (by CLO test or stool antigen test) Active inflammatory bowel disease Eosinophilic gastroenteritis or eosinophilic esophagitis Acute renal failure Chronic renal failure (serum creatinine >3 mg/dL) and/or on hemodialysis or peritoneal dialysis Acute liver failure Any acute gastrointestinal process Any plausible structural or metabolic causes Heartburn as predominant symptom History of peptic ulcer

  • Symptom resolution with antisecretory therapy (PPI use for other reasons that did not resolve FD symptoms will be allowed)
  • History of gastrointestinal tract surgery (including gastrectomy, gastric bypass surgery, and small or large bowel resection)
  • History of any serious medical condition (e.g., cancer)
  • Use of narcotic analgesics greater than three days per week
  • Current pregnancy or breastfeeding within the last 8 weeks
  • Uncontrolled diabetes (indicated by ≥7%) by chart
  • Intellectual disability by history
  • Current substance/alcohol use disorder within the past month
  • Current/history of psychosis (by Mini-International Neuropsychiatric Interview (MINI-Screen)
  • Current mania (by Mini-International Neuropsychiatric Interview (MINI-Screen) (defined as any manic episodes within the past 12 months)
  • Active suicidal ideation (by MINI-Screen)
  • Psychiatric disorder that would warrant independent attention (by Mini-International - Neuropsychiatric Interview (MINI-Screen))
  • Current enteral or parenteral feeding
  • Plans to initiate another psychotherapy or pregnancy in the concurrent study period
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Cognitive Behavioral Therapy

    Subjects will receive cognitive behavioral therapy for functional dyspepsia with avoidant restrictive food intake disorder.

    Behavioral: Cognitive Behavioral Therapy

  • No intervention
    Usual Care

    In the usual care condition, participants will be allowed to continue with treatment they are already receiving at the time of randomization, and we will collect detailed data on the nature of these interventions. Participants will be allowed to pursue non study treatments in this condition.

Interventions

  • BehavioralCognitive Behavioral Therapy

    Eight 1-hour sessions delivered weekly via the MGH-approved secure video platform Enterprise Zoom. Skills include: education about gut-brain regulation and weight loss, and regularizing eating to improve hunger and satiety cues; techniques to facilitate weight gain with targets of increased food volume and variety; and plan for maintenance of treatment gains.

06

What researchers measure

Primary outcomes

  1. Enrollment

    At the end of the study, we will calculate the percentage of participants who consent to initiate the study from the total who are offered.

    Time frame: Throughout study completion, an average of 3 years

  2. Assessment completion

    At the end of the study, we will calculate the percentage of participants who complete all assessments in each CBT and usual care groups.

    Time frame: Throughout study completion, an average of 3 years

  3. Retention

    At the end of the study, we will calculate the percentage of participants who complete at least 6 of the 8 CBT sessions.

    Time frame: Throughout study completion, an average of 3 years

  4. Interventionist Fidelity ratings

    At the end of the study, we will calculate fidelity, which measures the percentage of sessions that 100% of the CBT content was delivered.

    Time frame: Throughout study completion, an average of 3 years

  5. Client Satisfaction

    The Client Satisfaction Questionnaire (CSQ) is an 8 item self-report measure that assesses treatment satisfaction. Higher scores indicate greater treatment satisfaction.

    Time frame: Week 12

Secondary outcomes

  1. Short Form Nepean Dyspepsia Inventory (SF-NDI)

    The Short Form Nepean Dyspepsia Inventory (SF-NDI) includes a 15 item symptoms checklist to assess functional dyspepsia symptom severity. It also includes 10 items scored on a 5-point Likert scale measuring functional dyspepsia-related quality of life; subscales include interference with daily activities, knowledge/control, tension, work/study, and eating/drinking.

    Time frame: Weeks 0, 6, and 12

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05587127
Responsible party
Helen B. Murray, PHD (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Oct 19, 2022
Start date
Nov 30, 2022
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Sep 25, 2025

Study contacts

Blythe Peterson, BS
Contact
GIbehavioralresearch@mgh.harvard.edu
617-643-7884
Helen Burton Murray, PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion